Established in 2003, Unibest Industry is a global enterprise built upon the core values of being United, Networked, Innovative, Beyond, Efficient, Satisfied, and Technological. The company operates two primary business segments: international trading and licensing. The trading division focuses on pharmaceutical APIs, intermediates, and Biopharma products, with a significant presence in European and American markets, supported by its own CDMO facilities. The licensing division facilitates in-licensing and out-licensing of drug candidates and finished products, having successfully completed numerous transactions for innovative drugs, generic drugs, and chemical intermediates. Through its expanding network of business centers in Asia, Europe, North America, and Oceania, Unibest has cultivated long-term partnerships with major multinational pharmaceutical corporations and achieved consistent annual profit growth.
Established business centers in Paris and NewYork, forming a dual-core structure in Europe and the U.S. to cover European market access and NorthAmerican commercialization resources.
Established anAuckland business center in New Zealand, setting up a new overseas foothold forAsia-Pacific market expansion.
Established SingaPharma Pte. Ltd. to build a platform for pharmaceutical import and licensing in theAsia-Pacific region.
Focused on technological breakthroughs Shanghai Unibest Biomedical dedicated to the R&D of high-end intermediates Zhejiang Tize Biomedical specialized in AI drug design + continuous flow technology Nanjing Daoyi Biomedical focused on large-molecule LNP delivery systems.
Invested in Shenzhen Aoqi Bio-Tech, developing a dual-track approach for improved new drugs and drug delivery systems.
Invested in Guangzhou Taqing Environmental, supporting the green production transformation in the chemical and pharmaceutical industries.
Established Ningbo Advirtue Biomedical Technology Co., Ltd., focusing on early-stage biomedical projects
Acquired a stake in Xi'an Caijing Opto-Electrical Science&Technology Co.,Ltd., venturing into the field of pharmaceutical materials.
Invested in Shanghai Qinlong Chemical (CDMO base), completing the full industry chain layout and integrating R&D, production, and sales.
Founded Shanghai Unibest Biopharma, initiating a strategic upgrade to focus on independent technology R&D in the pharmaceutical sector.
Established Unibest Industrial, starting with chemical trading to lay the foundation for the supply chain.
· 25 years of experience in global chemical trade and biopharmaceutical investment;
· Founded Unibest and several other enterprises.
· Made strategic equity investments in multiple biopharmaceutical companies;
· Professor at the School of Pharmacy, Lanzhou University;
· Executive Chairman of the Fourth Board of Directors of the Oriental Wisdom Ningbo Alumni Association;
· Head of External Business of Zhejiang Sinochem Ningbo, Spearheaded pesticide and pharmaceutical intermediate exports, establishing foundational
industry expertise;
· Department of Economics and Management, Zhejiang University of Technology;
· CEIBS EMBA.
· 21 years of experience in management, business operations, and portfolio listing;
· Senior Manager of Pharmaceutical Project Operations at Roche;
· Director of Technical Marketing, Fujifilm Wako Pharmaceutical;
· Founder of WuXi Biologics Suzhou Base (CMAB Pharmaceuticals);
· Founder of several start-up companies;
· Global Chief Commercial Officer of Shanghai Cell Therapy Group;
· Doctoral degree in Pharmaceutical Management from the University of Otago;
· Master of Pharmaceutical Science, University of Auckland.
· Graduated from Zhejiang University in 1997;
· Engaged in software development work at the Third
· Research Institute of the Ministry of Posts and Telecommunications after graduation, and served as the youngest research director;One of the three founders of Unibest;
· With over 20 years of working experience in the pharmaceutical industry;
· Has established cooperation with more than 20 globally renowned pharmaceutical companies, with an annual sales volume of over 30 million USD;
· Has successfully expanded the business from Pharma to Biopharma.
· Joined Unibest in 2009 and currently serves as one of the company's partners;
· Over 16 years of hands-on experience in the pharmaceutical industry;
· More than 8 years of business operations and team management expertise at Fortune 500 companies;
· Leads the CDMO business for pharmaceutical intermediates, successfully built an integrated R&D, production, and sales platform, driving Unibest's strategic upgrade towards global high-end manufacturing;
· Full-cycle responsibility for dozens of CDMO projects with successful delivery, generating cumulative output value exceeding RMB 100 million;
· Master of Business Administration (MBA), Fudan University
Compliance & Green production
Sustainable development response
Social responsibilities
Ethics and compliance
